Centessa Pharmaceuticals plc · Q4 2022 earnings

Briefing

Centessa Pharmaceuticals reported its Q4 and full year 2022 financial results and recent business progress.

Centessa Pharmaceuticals reported a net loss of $43.2 million for the fourth quarter ended December 31, 2022, and cash and cash equivalents of $393.6 million as of December 31, 2022, which is expected to fund operations into 2026.

• Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study
• First subject dosed in Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumors; Preclinical data from second LockBody program targeting PD-L1xCD3 expected in 2023
• Nominated ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist, as product candidate with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023
• Cash runway into 2026

Headline financials

Revenue & EPS history

Centessa Pharmaceuticals expects to provide further updates on preclinical programs, including MGX292, as they advance towards clinical studies. The registrational program for hemophilia B is ongoing. The Company expects to share data from Part 5 of the OLE of the Phase 2a study of SerpinPC, subject to completion, at a scientific meeting this year. The Phase 1/2a first-in-human clinical study for Solid Tumors –PD-L1xCD47 LockBody (LB101) is ongoing. The Company expects to name a product candidate and share preclinical data this year for PD-L1xCD3 LockBody (Undisclosed). The Company expects to share preclinical data at a scientific meeting later this year for Narcolepsy and Other Sleep Disorders (ORX750).